To the full analysis
Bio-Rad Laboratories stock: growth
BIOBio-Rad Laboratories reported $2.58B in revenue for fiscal 2025, up 0.7% on the prior year, up 0.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
3.8%
per year from 2006 to 2025, per share 3.6%
Earnings (Annual rate)
11.1%
per year from 2006 to 2025, per share 10.9%
Free cash flow (Annual rate)
9.6%
per year from 2006 to 2025, per share 9.4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 0.3% | 2.5% | 3.8% |
| Revenue per share | 2.1% | 3.2% | 3.6% |
| Earnings | −27.6% | 21.0% | 11.1% |
| Earnings per share | −26.3% | 22.2% | 10.9% |
| Free cash flow | −4.7% | 17.8% | 9.6% |
| Free cash flow per share | −3.0% | 18.6% | 9.4% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.27B | $103.26M | $65.24M |
| 2007 | $1.46B | $92.99M | $128.91M |
| 2008 | $1.76B | $89.51M | $102.56M |
| 2009 | $1.78B | $144.62M | $248.71M |
| 2010 | $1.93B | $185.49M | $133.38M |
| 2011 | $2.07B | $178.22M | $159.41M |
| 2012 | $2.07B | $169.23M | $121.83M |
| 2013 | $2.13B | $77.79M | $61.78M |
| 2014 | $2.18B | $88.85M | $136.83M |
| 2015 | $2.02B | $113.09M | $72.84M |
| 2016 | $2.07B | $28.13M | $74.5M |
| 2017 | $2.16B | $114.74M | −$10.99M |
| 2018 | $2.29B | $361M | $155.67M |
| 2019 | $2.31B | $1.76B | $359.37M |
| 2020 | $2.55B | $3.81B | $476.41M |
| 2021 | $2.92B | $4.25B | $535.72M |
| 2022 | $2.8B | −$3.63B | $80.29M |
| 2023 | $2.67B | −$637.32M | $218.26M |
| 2024 | $2.57B | −$1.84B | $266.2M |
| 2025 | $2.58B | $759.9M | $374.6M |
Revenue by segment
How Bio-Rad Laboratories, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Clinical Diagnostics60%
- Life Science40%
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Diagnostics | $1.32B | $1.36B | $1.41B | $1.41B | $1.31B | $1.52B | $1.45B | $1.49B | $1.54B | $1.56B | 60.5% |
| Life Science | $730.7M | $785.2M | $861.7M | $885.9M | $1.23B | $1.4B | $1.35B | $1.18B | $1.03B | $1.02B | 39.5% |
| Total revenue | $2.07B | $2.16B | $2.29B | $2.31B | $2.55B | $2.92B | $2.8B | $2.67B | $2.57B | $2.58B | 100% |
Revenue by region
Where Bio-Rad Laboratories, Inc. generates its revenue.
- United States40%
- Europe34%
- Asia Pacific20%
- Americas6%
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $770.6M | $800.2M | $863.6M | $899.1M | $1B | $1.13B | $1.16B | $1.12B | $1.04B | $1.02B | 39.6% |
| Europe | $742.2M | $758.5M | $792M | $770.3M | $857.7M | $946.9M | $851.9M | $819.8M | $834.1M | $881.8M | 34.1% |
| Asia Pacific | $427.1M | $461.3M | $495.5M | $505M | $546.5M | $688.4M | $639.4M | $563M | $521.6M | $513.3M | 19.9% |
| Americas | $128.3M | $140.2M | $138.3M | $137.3M | $136.6M | $156.6M | $155.4M | $166.6M | $169.3M | $165.4M | 6.4% |
| Total revenue | $2.07B | $2.16B | $2.29B | $2.31B | $2.55B | $2.92B | $2.8B | $2.67B | $2.57B | $2.58B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.